Home The Word Brain My Amedeo FAQ Privacy About   

As of October 2023, Amedeo had
12,263 active subscribers


  Free Subscription

Articles published in J Med Virol

Retrieve available abstracts of 122 articles:
HTML format

Single Articles

    November 2023
  1. KRUMBHOLZ A, Marcic A, Valentin M, Schemmerer M, et al
    Hepatitis A outbreak in a refugee shelter in Kiel, northern Germany.
    J Med Virol. 2023;95:e29185.
    PubMed     Abstract available

  2. LI W, Zhang H, Ren A, Fan W, et al
    Systemic lupus erythematosus is associated with lower risk of hepatitis B virus infection: A multivariable Mendelian randomization study in East Asian population.
    J Med Virol. 2023;95:e29226.
    PubMed     Abstract available

    October 2023
  3. FU MX, Simmonds P, Andreani J, Baklan H, et al
    Ultrasensitive PCR system for HBV DNA detection: Risk stratification for occult hepatitis B virus infection in English blood donors.
    J Med Virol. 2023;95:e29144.
    PubMed     Abstract available

  4. WU WJ, Lin CL, Liu CJ, Huang YW, et al
    Lifetime risk of liver-related outcomes and determinants in male inactive carriers of chronic hepatitis B.
    J Med Virol. 2023;95:e29138.
    PubMed     Abstract available

  5. LIU J, Zhang H, Kong J, Liu S, et al
    Alleviated symptoms of SARS-CoV-2 Omicron variant infection in chronic hepatitis B patients with immune control.
    J Med Virol. 2023;95:e29173.
    PubMed     Abstract available

  6. ZHANG M, Chen S, Wu X, Zhou J, et al
    Persistent steatosis correlates with decreased fibrosis regression during anti-HBV treatment in patients with chronic HBV infection.
    J Med Virol. 2023;95:e29156.
    PubMed     Abstract available

  7. ZHAN Y, Tao Q, Lang Z, Lin L, et al
    Serum ribonucleotide reductase M2 is a potential biomarker for diagnosing and monitoring liver fibrosis in chronic hepatitis B patients.
    J Med Virol. 2023;95:e29157.
    PubMed     Abstract available

  8. ELIZALDE MM, Giadans CG, Campos RH, Flichman DM, et al
    Impact of core protein naturally selected mutants associated with HBeAg-negative status in HBV biosynthesis.
    J Med Virol. 2023;95:e29195.
    PubMed     Abstract available

  9. REN H, Chen X, Wang J, Chen Y, et al
    Temporal and structural patterns of hepatitis B virus integrations in hepatocellular carcinoma.
    J Med Virol. 2023;95:e29187.
    PubMed     Abstract available

  10. YANG D, Zou J, Guan G, Feng X, et al
    The A1762T/G1764A mutations enhance HBV replication by alternating viral transcriptome.
    J Med Virol. 2023;95:e29129.
    PubMed     Abstract available

  11. TANG L, Li Q, Chen L, Li X, et al
    IL-21 collaborates with anti-TIGIT to restore NK cell function in chronic HBV infection.
    J Med Virol. 2023;95:e29142.
    PubMed     Abstract available

    September 2023
  12. SHEN Z, Zhang S, Jiang Q, Liu N, et al
    Lipid nanoparticle-mediated delivery of IL-21-encoding mRNA induces viral clearance in mouse models of hepatitis B virus persistence.
    J Med Virol. 2023;95:e29062.
    PubMed     Abstract available

  13. PENG X, Shi Y, Zhang B, Xu C, et al
    Establishment of nucleic acid sensing pathways-based model in predicting response to immunotherapy and targeted drug in hepatitis virus-related hepatocellular carcinoma.
    J Med Virol. 2023;95:e29084.
    PubMed     Abstract available

  14. SUZUKI T, Matsuura K, Watanabe T, Matsui T, et al
    Kinetics of HBcrAg and HBsAg using highly sensitive iTACT assays in chronic hepatitis B patients with HBsAg seroclearance.
    J Med Virol. 2023;95:e29109.
    PubMed     Abstract available

  15. LIU C, Guo M, Han L, Lu J, et al
    Construction and characterization of a new hepatitis C virus genotype 6a subgenomic replicon that is prone to render the sofosbuvir resistance.
    J Med Virol. 2023;95:e29103.
    PubMed     Abstract available

    August 2023
  16. GUO M, Zhao L, Jiang C, Jia CC, et al
    Multiomics analyses reveal pathological mechanisms of HBV infection and integration in liver cancer.
    J Med Virol. 2023;95:e28980.
    PubMed     Abstract available

  17. ZENG DY, Chen Z, Hong MZ, Jiang LP, et al
    Traditional Chinese medicine invigorating the spleen and kidney promotes HBsAg seroclearance in the mouse model.
    J Med Virol. 2023;95:e28979.
    PubMed     Abstract available

  18. ROY A, Saade C, Josset L, Clement B, et al
    Determinants of protection against SARS-CoV-2 Omicron BA.1 and Delta infections in fully vaccinated outpatients.
    J Med Virol. 2023;95:e28984.
    PubMed     Abstract available

  19. LIM CK, Tran BM, Flanagan D, McCartney E, et al
    Assessment of HBV infection and inter-host cellular responses using intrahepatic cholangiocyte organoids.
    J Med Virol. 2023;95:e28975.
    PubMed     Abstract available

  20. YE X, Li T, Yu B, Zeng J, et al
    The high prevalence of occult hepatitis B infections among the partners of chronically infected HBV blood donors emphasizes the potential residual risk to blood safety.
    J Med Virol. 2023;95:e29006.
    PubMed     Abstract available

  21. ADACHI E, Saito M, Kikuchi T, Ikeuchi K, et al
    Incidence of sexually transmitted hepatitis C virus infection among men who have sex with men in Japan from 2009 to 2023.
    J Med Virol. 2023;95:e29039.
    PubMed     Abstract available

    July 2023
  22. GATES S, Andreani J, Dewar R, Smith DB, et al
    Postpandemic rebound of adeno-associated virus type 2 (AAV2) infections temporally associated with an outbreak of unexplained severe acute hepatitis in children in the United Kingdom.
    J Med Virol. 2023;95:e28921.
    PubMed     Abstract available

  23. HOGAN G, Winer BY, Ahodantin J, Sellau J, et al
    Persistent hepatitis B virus and HIV coinfections in dually humanized mice engrafted with human liver and immune system.
    J Med Virol. 2023;95:e28930.
    PubMed     Abstract available

  24. KANG NL, Gao YH, Lin MX, Wu LY, et al
    Development a novel nomogram model for predicting significant hepatic histological changes in chronic hepatitis B virus carriers.
    J Med Virol. 2023;95:e28943.
    PubMed     Abstract available

  25. LUO M, Zhang L, Yang C, Zhou B, et al
    CXCL13 variant predicts pegylated-interferon alpha treatment response in HBeAg-positive chronic hepatitis B patients.
    J Med Virol. 2023;95:e28963.
    PubMed     Abstract available

  26. ZHAO L, Yuan H, Wang Y, Geng Y, et al
    HBV confers innate immune evasion through triggering HAT1/acetylation of H4K5/H4K12/miR-181a-5p or KPNA2/cGAS-STING/IFN-I signaling.
    J Med Virol. 2023;95:e28966.
    PubMed     Abstract available

  27. LARA-AGUILAR V, Crespo-Bermejo C, Llamas-Adan M, Grande-Garcia S, et al
    HCV spontaneous clearers showed low senescence profile in people living with HIV under long ART.
    J Med Virol. 2023;95:e28955.
    PubMed     Abstract available

  28. ZHANG J, Zhang Y, Khanal S, Cao D, et al
    Synthetic gRNA/Cas9 ribonucleoprotein targeting HBV DNA inhibits viral replication.
    J Med Virol. 2023;95:e28952.
    PubMed     Abstract available

  29. YAO YX, Chen Y, Huang D, Liu C, et al
    RNA-binding motif protein 24 inhibits HBV replication in vivo.
    J Med Virol. 2023;95:e28969.
    PubMed     Abstract available

    June 2023
  30. LI J, Li J, Chen S, Xu W, et al
    Clinical isolates of hepatitis B virus genotype C have higher in vitro transmission efficiency than genotype B isolates.
    J Med Virol. 2023;95:e28879.
    PubMed     Abstract available

  31. SHI L, Wang Y, Cao X, Huang W, et al
    Increasing positive rate of IgG against hepatitis E virus with steady IgM positivity and clinical incidence: A retrospective seroprevalence time series analysis of HEV from 2012 to 2021 in Chongqing, China.
    J Med Virol. 2023;95:e28872.
    PubMed     Abstract available

  32. SUGIYAMA R, Takahara O, Yahata Y, Kanou K, et al
    Nationwide epidemiologic and genetic surveillance of hepatitis E in Japan, 2014-2021.
    J Med Virol. 2023;95:e28886.
    PubMed     Abstract available

  33. ZHENG L, Wang L, Lu F
    Looking back on the outbreak of acute severe hepatitis with unknown etiology in children in 2022: What do we know now and where do we go from here?
    J Med Virol. 2023;95:e28890.

    April 2023
  34. XIE Z, Shen S, Huang K, Wang W, et al
    Mitochondrial HIGD1A inhibits hepatitis B virus transcription and replication through the cellular PNKD-NF-kappaB-NR2F1 nexus.
    J Med Virol. 2023;95:e28749.
    PubMed     Abstract available

  35. HE L, Cai Q, Liang X, Xin J, et al
    ETS2 alleviates acute-on-chronic liver failure by suppressing excessive inflammation.
    J Med Virol. 2023;95:e28710.
    PubMed     Abstract available

    March 2023
  36. CHEN Z, Huang T, He T, Zha G, et al
    Humoral responses after primary and booster SARS-CoV-2 inactivated vaccination in patients with chronic hepatitis B virus infection: a longitudinal observational study.
    J Med Virol. 2023 Mar 22. doi: 10.1002/jmv.28695.
    PubMed     Abstract available

  37. WU B, Tobe RG, Yan M, Lin H, et al
    Trends of Global Burden Related to HBV and HCV from 1990 to 2019: An Age-Period-Cohort Analysis.
    J Med Virol. 2023 Mar 11. doi: 10.1002/jmv.28663.
    PubMed     Abstract available

  38. LIU Y, Chen M
    Is nonalcoholic fatty liver disease a predictor of treatment response in chronic hepatitis B?
    J Med Virol. 2023 Mar 10. doi: 10.1002/jmv.28654.
    PubMed     Abstract available

  39. XU W, Zhu S, Yang L, Li Z, et al
    Safety and efficacy of double plasma molecular adsorption system with sequential low-volume plasma exchange in intermediate-stage hepatitis B virus-related acute-on-chronic liver failure.
    J Med Virol. 2023 Mar 10. doi: 10.1002/jmv.28650.
    PubMed     Abstract available

  40. PISATURO M, Alessio L, Starace M, Macera M, et al
    J Med Virol. 2023 Mar 10. doi: 10.1002/jmv.28665.
    PubMed     Abstract available

  41. GAO L, Gao Y, Han K, Wang Z, et al
    FBXO11 amplifies type I interferon signaling to exert antiviral effects by facilitating the assemble of TRAF3-TBK1-IRF3 complex.
    J Med Virol. 2023 Mar 10. doi: 10.1002/jmv.28655.
    PubMed     Abstract available

  42. FENG Z, Huang P, Zhang J, Xia X, et al
    KIR2DL4/HLA-G polymorphisms were associated with HCV infection susceptibility among Chinese high-risk population.
    J Med Virol. 2023 Mar 8. doi: 10.1002/jmv.28645.
    PubMed     Abstract available

  43. CHARRE C, Regue H, Deny P, Josset L, et al
    Improved Hepatitis Delta Virus genome characterization by single molecule full-length genome sequencing combined with VIRiONT pipeline.
    J Med Virol. 2023 Mar 6. doi: 10.1002/jmv.28634.
    PubMed     Abstract available

  44. CAI T, Yue T, Xu M, Zhang P, et al
    Poor glycemic control in type-2 diabetic patients infected with hepatitis B: a retrospective propensity-matched study.
    J Med Virol. 2023 Mar 4. doi: 10.1002/jmv.28635.
    PubMed     Abstract available

  45. WANG Q, Liu Y, Luo J, Yang S, et al
    A systematic comparison reveals dynamic differences in early adaptive immune responses of acute-resolving versus chronic HBV replication.
    J Med Virol. 2023;95:e28670.
    PubMed     Abstract available

  46. REN F, Hu J, Dang Y, Deng H, et al
    Sphondin efficiently blocks HBsAg production and cccDNA transcription through promoting HBx degradation.
    J Med Virol. 2023;95:e28578.
    PubMed     Abstract available

    February 2023
  47. TU W, Liu J, Qian F, Zhu L, et al
    Ubiquitin E3 ligase beta-TrCP negatively regulates surface protein of hepatitis B virus.
    J Med Virol. 2023 Feb 27. doi: 10.1002/jmv.28620.
    PubMed     Abstract available

  48. LIAO H, Zhang H, Shao J, Li X, et al
    Nucleos(t)ide analogues altered quasispecies composition of hepatitis B virus (HBV)-resistant mutations in serum HBV DNA and serum HBV RNA.
    J Med Virol. 2023 Feb 25. doi: 10.1002/jmv.28612.
    PubMed     Abstract available

  49. KASHYAP N, Islam M, Kaur H, Tiwari D, et al
    Oxidative stress - a key determinant of complications and negative outcome in Hepatitis E virus infected pregnancies: a comprehensive account involving cases from northeast India.
    J Med Virol. 2023 Feb 13. doi: 10.1002/jmv.28576.
    PubMed     Abstract available

  50. SHUI LP, Zhu Y, Duan XQ, Chen YT, et al
    HBsAg (-)/HBsAb (-)/HBeAg (-)/HBeAb (+)/HBcAb (+) predicts a high risk of hepatitis B reactivation in patients with B-cell lymphoma receiving rituximab based immunochemotherapy.
    J Med Virol. 2023 Feb 3. doi: 10.1002/jmv.28549.
    PubMed     Abstract available

  51. NOT A, Saludes V, Galvez M, Miralpeix A, et al
    Usefulness of dried blood spot samples for monitoring hepatitis C treatment outcome and reinfection among people who inject drugs in a test-and-treat program.
    J Med Virol. 2023 Feb 2. doi: 10.1002/jmv.28544.
    PubMed     Abstract available

  52. CHEN S, Wang B, Zhou J, Wu X, et al
    A new glutamine synthetase index to evaluate hepatic lobular restoration in advanced fibrosis during anti-HBV therapy.
    J Med Virol. 2023;95:e28555.
    PubMed     Abstract available

    January 2023
  53. XIE J, Ding Y, Li X, Pu R, et al
    Association of ESR1 gene polymorphisms with the susceptibility to Hepatitis B virus infection and the clinical outcomes.
    J Med Virol. 2023 Jan 20. doi: 10.1002/jmv.28510.
    PubMed     Abstract available

  54. HASSEBROEK AM, Sooryanarain H, Lynn Heffron C, Hawks SA, et al
    A hepatitis B virus core antigen-based virus-like particle vaccine expressing SARS-CoV-2 B and T cell epitopes induces epitope-specific humoral and cell-mediated immune responses but confers limited protection against SARS-CoV-2 infection.
    J Med Virol. 2023 Jan 19. doi: 10.1002/jmv.28503.
    PubMed     Abstract available

  55. TANG Y, Fan R, Lan Z, Xie Q, et al
    Impact of nonalcoholic fatty liver disease status change on antiviral efficacy of nucleos(t)ide analogues in HBeAg-positive chronic hepatitis B.
    J Med Virol. 2023 Jan 19. doi: 10.1002/jmv.28501.
    PubMed     Abstract available

  56. SUDA G, Baba M, Yamamoto Y, Sho T, et al
    Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitis.
    J Med Virol. 2023 Jan 4. doi: 10.1002/jmv.28452.
    PubMed     Abstract available

  57. XIANG Z, Jiang C, Yang J, Huang L, et al
    Serum extracellular vesicle-derived ASS1 is a promising predictor for the occurrence of HEV-ALF.
    J Med Virol. 2023;95:e28425.
    PubMed     Abstract available

  58. MOHAMED AA, Esmail OE, Ibrahim AMA, Makled S, et al
    The role of PRDM1 gene polymorphism in the progression of hepatocellular carcinoma in Egyptian patients.
    J Med Virol. 2023;95:e28343.
    PubMed     Abstract available

    December 2022
  59. KAR A, Samanta A, Mukherjee S, Barik S, et al
    The HBV web: An insight into molecular interactomes between the Hepatitis B virus and its host en route to hepatocellular carcinoma.
    J Med Virol. 2022 Dec 27. doi: 10.1002/jmv.28436.
    PubMed     Abstract available

  60. TUNCEL B, Kaygusuz S, Sayin Kocakap DB, Aksoy E, et al
    J Med Virol. 2022 Dec 7. doi: 10.1002/jmv.28376.
    PubMed     Abstract available

    November 2022
  61. ARANDHARA VL, Patrick McClure C, Tarr AW, Chappell S, et al
    J Med Virol. 2022 Nov 22. doi: 10.1002/jmv.28331.
    PubMed     Abstract available

  62. CHEN J, Li F, Tian J, Xie X, et al
    Varicella Zoster Virus Reactivation Following COVID-19 Vaccination in patients with autoimmune inflammatory rheumatic diseases: A cross-sectional Chinese study of 318 cases.
    J Med Virol. 2022 Nov 13. doi: 10.1002/jmv.28307.
    PubMed     Abstract available

  63. SHI Y, Jin X, Wu S, Liu J, et al
    Release of hepatitis B virions is positively regulated by glucose-regulated protein 78 through direct interaction with preS1.
    J Med Virol. 2022 Nov 2. doi: 10.1002/jmv.28271.
    PubMed     Abstract available

    October 2022
  64. LUCIANI L, Bichon A, Mortier C, Bourenne J, et al
    Acute hepatitis associated with an echovirus 9 infection in a heart transplant recipient.
    J Med Virol. 2022 Oct 30. doi: 10.1002/jmv.28262.
    PubMed     Abstract available

  65. CHEN J, Yu S, Lang Z, Jin Y, et al
    Development and validation of a potential biomarker to improve the assessment of liver fibrosis progression in patients with chronic hepatitis B.
    J Med Virol. 2022 Oct 18. doi: 10.1002/jmv.28239.
    PubMed     Abstract available

  66. KANEKO S, Kurosaki M, Mashiba T, Marusawa H, et al
    Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B.
    J Med Virol. 2022 Oct 12. doi: 10.1002/jmv.28210.
    PubMed     Abstract available

  67. ZHANG F, Yang Z, Dai C, He Q, et al
    Efficacy of an accelerated vaccination schedule against hepatitis E virus infection in pregnant rabbits.
    J Med Virol. 2022 Oct 6. doi: 10.1002/jmv.28193.
    PubMed     Abstract available

    September 2022
  68. LUO J, Liang X, Xin J, Li P, et al
    Serum ferritin diagnosis and prediction of hepatitis B virus-related acute-on-chronic liver failure.
    J Med Virol. 2022 Sep 29. doi: 10.1002/jmv.28183.
    PubMed     Abstract available

  69. ADEBOYEJO K, King B, Tsoleridis T, Tarr A, et al
    Hepatitis C subtyping assay failure in UK patients born in Sub-Saharan Africa: implications for global treatment and elimination.
    J Med Virol. 2022 Sep 27. doi: 10.1002/jmv.28178.
    PubMed     Abstract available

  70. YU X, Zheng Y, Zeng D, Zhou Y, et al
    Decreased frequency of a novel T-lymphocyte subset, CD3(+) CD4(-) CD7(+) CD57(-) T cells, in hepatitis B virus-related end-stage liver disease might contribute to disease progression.
    J Med Virol. 2022 Sep 6. doi: 10.1002/jmv.28129.
    PubMed     Abstract available

  71. CHALID MT, Turyadi, Ie SI, Sjahril R, et al
    A cautionary note to hepatitis B e antigen (HBeAg)-negative test results in pregnant women in an area prevalent of HBeAg-negative chronic hepatitis B.
    J Med Virol. 2022 Sep 5. doi: 10.1002/jmv.28125.
    PubMed     Abstract available

    August 2022
  72. PRICE AS, Nelson AK, Ghosh A, Kottilil S, et al
    A Phase 2 Open Label Study of Ledipasvir/Sofosbuvir for 12 Weeks in Subjects with Hepatitis B Virus Infection.
    J Med Virol. 2022 Aug 31. doi: 10.1002/jmv.28105.
    PubMed     Abstract available

  73. CHEN Z, Yuan Y, Yang D, Luo M, et al
    Antiviral activities of Polygonum Perfoliatum L. extract and related phenolic acid constituents against hepatitis B virus.
    J Med Virol. 2022 Aug 24. doi: 10.1002/jmv.28087.
    PubMed     Abstract available

    Potential mechanisms by which adeno-associated virus type 2 causes unexplained hepatitis in children.
    J Med Virol. 2022 Aug 22. doi: 10.1002/jmv.28082.
    PubMed     Abstract available

  75. SARFARAZ N, Somarowthu S, Bouchard MJ
    The Interplay of Long Non-Coding RNAs and Hepatitis B Virus.
    J Med Virol. 2022 Aug 9. doi: 10.1002/jmv.28058.
    PubMed     Abstract available

    July 2022
  76. RUPASINGHE D, Choi JY, Yunihastuti E, Kiertiburanakul S, et al
    Factors associated with high alanine aminotransferase (ALT) and cirrhosis in people living with HIV on combination antiretroviral treatment (cART) in the Asia-Pacific.
    J Med Virol. 2022 Jul 22. doi: 10.1002/jmv.28019.
    PubMed     Abstract available

  77. CHEEMA HA, Shahid A, Aziz H
    Severe acute pediatric hepatitis: the undue emphasis on adenovirus needs to be reassessed.
    J Med Virol. 2022 Jul 20. doi: 10.1002/jmv.28014.
    PubMed     Abstract available

  78. LIAN J, Kuang W, Jia H, Lu Y, et al
    Pegylated interferon-alpha-2b combined with tenofovir disoproxil fumarate, granulocyte-macrophage colony-stimulating factor, and hepatitis B vaccine treatment for naive HBeAg-positive chronic hepatitis B patients: A prospective, multicenter, randomize
    J Med Virol. 2022 Jul 14. doi: 10.1002/jmv.28003.
    PubMed     Abstract available

  79. ZHANG Q, Liang J, Yin J, Jiang Y, et al
    Real-life impact of tenofovir disoproxil fumarate and entecavir therapy on lipid profile, glucose and uric acid in chronic hepatitis B patients.
    J Med Virol. 2022 Jul 6. doi: 10.1002/jmv.27977.
    PubMed     Abstract available

  80. RATHO RK, Thakur V, Arya S, Singh MP, et al
    Placenta as a site of HEV replication and inflammatory cytokines modulating the immunopathogenesis of HEV in pregnant women.
    J Med Virol. 2022;94:3457-3463.
    PubMed     Abstract available

    June 2022
  81. ZHONG S, Liu Z, Zhou Y, Zhang T, et al
    Longitudinal mapping of hepatitis B vaccine-induced B-cell linear epitopes in healthy individuals.
    J Med Virol. 2022 Jun 8. doi: 10.1002/jmv.27926.
    PubMed     Abstract available

  82. ZHENG XQ, Li X, Liu J, Shi L, et al
    Horizontal transmission might be a common route of hepatitis B virus exposure in highly endemic areas.
    J Med Virol. 2022 Jun 2. doi: 10.1002/jmv.27905.
    PubMed     Abstract available

  83. OHTA A, Ogawa E, Murata M, Matsumoto Y, et al
    Impact of the PNPLA3 genotype on the risk of hepatocellular carcinoma after hepatitis C virus eradication.
    J Med Virol. 2022 Jun 2. doi: 10.1002/jmv.27904.
    PubMed     Abstract available

    May 2022
  84. QI X, Li F, Zhang Y, Zhu H, et al
    STAT4 genetic polymorphism significantly affected HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients receiving Peginterferon-alpha therapy: A prospective cohort study in China Running title: STAT4 variation affecting response to PegIF
    J Med Virol. 2022 May 24. doi: 10.1002/jmv.27880.
    PubMed     Abstract available

  85. ZENG QL, Yu ZJ, Lv J, Zhang HX, et al
    Sofosbuvir-based Therapy for Late Pregnant Women and Infant with Severe Chronic Hepatitis C: A Case Series Study.
    J Med Virol. 2022 May 20. doi: 10.1002/jmv.27877.
    PubMed     Abstract available

  86. LIANG LY, Yip TC, Lai JC, Lam AS, et al
    Tenofovir alafenamide is associated with improved alanine aminotransferase and renal safety compared to tenofovir disoproxil fumarate.
    J Med Virol. 2022 May 17. doi: 10.1002/jmv.27863.
    PubMed     Abstract available

  87. HAKIM MS
    The recent outbreak of acute and severe hepatitis of unknown etiology in children: a possible role of human adenovirus infection?
    J Med Virol. 2022 May 16. doi: 10.1002/jmv.27856.
    PubMed     Abstract available

  88. XIE Z, Deng K, Xia Y, Zhang C, et al
    Efficacy and safety of direct-acting antiviral therapies and baseline predictors for treatment outcomes in hepatitis C patients: a multi-center, real-world study in Guangdong, China.
    J Med Virol. 2022 May 11. doi: 10.1002/jmv.27851.
    PubMed     Abstract available

  89. MALONGA GA, Dienta S, Traore FT, Maiga Z, et al
    Human Herpesvirus 8 seroprevalence among blood donors in Mali.
    J Med Virol. 2022 May 11. doi: 10.1002/jmv.27850.
    PubMed     Abstract available

  90. KOC OM, van Oorschot E, Brandts L, Lashof AO, et al
    Timing of primary three dose hepatitis B vaccination and postvaccination serologic testing among a large cohort of healthy adults.
    J Med Virol. 2022 May 10. doi: 10.1002/jmv.27848.
    PubMed     Abstract available

    April 2022
  91. KHAN YH, Mallhi TH, Alanazi AS, Butt MH, et al
    Outbreak of Acute Hepatitis of Unknown etiology in Children; The Critical Role of Healthcare Professionals in Neutralizing Misleading Narratives during the COVID-19 Pandemic.
    J Med Virol. 2022 Apr 29. doi: 10.1002/jmv.27819.

  92. ZHANG C, Liu Y, Li J, Liu H, et al
    Dose-response relationship between qAnti-HBc and liver inflammation in chronic hepatitis B with normal or mildly elevated ALT based on liver biopsy.
    J Med Virol. 2022 Apr 13. doi: 10.1002/jmv.27779.
    PubMed     Abstract available

  93. ZHAO D, Yu S, Guo P, Zhang X, et al
    Identification of potential plasma markers for hepatitis B virus-related chronic hepatitis and liver fibrosis/cirrhosis.
    J Med Virol. 2022 Apr 5. doi: 10.1002/jmv.27761.
    PubMed     Abstract available

    March 2022
  94. LIN P, Wen DY, Pang JS, Liao W, et al
    Proteomics profiling of nontumor liver tissues identifies prognostic biomarkers in hepatitis B-related hepatocellular carcinoma.
    J Med Virol. 2022 Mar 21. doi: 10.1002/jmv.27732.
    PubMed     Abstract available

  95. YU J, Shi X, Yu H, Wu J, et al
    Impact of hepatitis-B-surface-antigen-positive grafts on liver transplantation in patients with benign and malignant liver disease.
    J Med Virol. 2022 Mar 7. doi: 10.1002/jmv.27703.
    PubMed     Abstract available

    February 2022
  96. WU J, Xu Y, Cui Y, Bortolanza M, et al
    Dynamic changes of serum metabolites associated with infection and severity of patients with acute hepatitis E infection.
    J Med Virol. 2022 Feb 23. doi: 10.1002/jmv.27669.
    PubMed     Abstract available

  97. JACKSON K, Holgate T, Tekoaua R, Nicholson S, et al
    Evaluation of dried blood spots for hepatitis B and D serology and nucleic acid testing.
    J Med Virol. 2022;94:642-648.
    PubMed     Abstract available

    January 2022
  98. MOREIRA LVL, Malheiros AP, Barbosa KMV, Freitas PEB, et al
    The first evidence of Hepatitis A virus subgenotype IIIA in the Eastern Brazilian Amazon, 1982-1983.
    J Med Virol. 2022 Jan 25. doi: 10.1002/jmv.27625.
    PubMed     Abstract available

  99. LUO M, Chen Z, Liu M, Liang Q, et al
    Inhibitory Activities of Ranunculus japonicus Thunb. Ethanol Extract against Hepatitis B Virus.
    J Med Virol. 2022 Jan 24. doi: 10.1002/jmv.27621.
    PubMed     Abstract available

  100. LEON FJF, Silva LLD, Santos AC, Duarte da Costa V, et al
    Immunological and virological aspects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and hepatitis C virus.
    J Med Virol. 2022 Jan 22. doi: 10.1002/jmv.27614.
    PubMed     Abstract available

  101. YU K, Mei Y, Wang Z, Liu B, et al
    LncRNA LINC00924 upregulates NDRG2 to inhibit epithelial-mesenchymal transition via sponging miR-6755-5p in hepatitis B virus-related hepatocellular carcinoma.
    J Med Virol. 2022 Jan 8. doi: 10.1002/jmv.27578.
    PubMed     Abstract available

    December 2021
  102. XIE Y, Ma H, Feng B, Song G, et al
    Combining the HBcrAg decline and HBV mutations predicts spontaneous HBeAg seroconversion in chronic hepatitis B patients during the immune clearance phase.
    J Med Virol. 2021 Dec 24. doi: 10.1002/jmv.27545.
    PubMed     Abstract available

  103. DENG H, Feng Q, Wu Y, Lin H, et al
    Immune response to hepatitis B vaccination in human immunodeficiency virus-positive patients in China: A 2-year retrospective study.
    J Med Virol. 2021 Dec 14. doi: 10.1002/jmv.27523.
    PubMed     Abstract available

    November 2021
  104. BOLINA-SANTOS E, Chaves DG, da Silva-Malta MCF, Carmo RA, et al
    HCV infection in hemophilia A patients is associated with altered cytokines and chemokines profile and might modulate the levels of FVIII inhibitor.
    J Med Virol. 2021 Nov 5. doi: 10.1002/jmv.27432.
    PubMed     Abstract available

  105. ZHENG S, Li M, Pan X, Huang X, et al
    Association of IL-32 rs28372698 polymorphism with active chronic HBV infection.
    J Med Virol. 2021;93:6236-6240.
    PubMed     Abstract available

    October 2021
  106. JI Q, Chu X, Zhou Y, Liu X, et al
    Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in hemodialysis patients.
    J Med Virol. 2021 Oct 2. doi: 10.1002/jmv.27374.
    PubMed     Abstract available

    September 2021
  107. WU J, Bortolanza M, Zhai G, Shang A, et al
    Gut Microbiota Dysbiosis Associated with Plasma Levels of Interferon-gamma and Viral Load in Patients with Acute Hepatitis E Infection.
    J Med Virol. 2021 Sep 22. doi: 10.1002/jmv.27356.
    PubMed     Abstract available

  108. KAZMI SK, Khan FMA, Natoli V, Hunain R, et al
    Viral hepatitis amidst COVID-19 in Africa: Implications and Recommendations.
    J Med Virol. 2021 Sep 10. doi: 10.1002/jmv.27330.
    PubMed     Abstract available

  109. NICOLINI LA, Menzaghi B, Molteni C, Vichi F, et al
    Comments on "Real-world re-treatment outcomes of direct-acting antiviral therapy failure in patients with chronic hepatitis C".
    J Med Virol. 2021 Sep 9. doi: 10.1002/jmv.27329.

  110. YAO K, Wang J, Wang L, Xia J, et al
    Association of anti-HBc and liver inflammation in HBeAg-negative chronic hepatitis B virus infected patients with normal ALT and detectable HBV DNA.
    J Med Virol. 2021 Sep 9. doi: 10.1002/jmv.27327.
    PubMed     Abstract available

    August 2021
  111. TARAFDAR S, Virata ML, Yan H, Zhong L, et al
    Multiple Epitopes of Hepatitis B Virus Surface Antigen Targeted by Human Plasma-derived Immunoglobulins Coincide with Clinically Observed Escape Mutations.
    J Med Virol. 2021 Aug 18. doi: 10.1002/jmv.27278.
    PubMed     Abstract available

  112. YAO Y, Shen Y, Shao H, Liu Y, et al
    Polymorphisms of RIG-I-like receptor influence HBV clearance in Chinese Han population.
    J Med Virol. 2021;93:4957-4965.
    PubMed     Abstract available

    July 2021
  113. WEI MT, Le MH, Landis C, Trinh H, et al
    Evaluation of ethnic influence in the application of a hepatocellular carcinoma predictive model for chronic hepatitis C.
    J Med Virol. 2021 Jul 5. doi: 10.1002/jmv.27168.
    PubMed     Abstract available

    June 2021
  114. LEUMI S, El Kassas M, Zhong J
    Hepatitis C virus-genotype 4: a poorly characterized endemic genotype.
    J Med Virol. 2021 Jun 29. doi: 10.1002/jmv.27165.
    PubMed     Abstract available

  115. TADA T, Kurosaki M, Nakamura S, Hasebe C, et al
    Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.
    J Med Virol. 2021 Jun 25. doi: 10.1002/jmv.27157.
    PubMed     Abstract available

  116. JI H, Chen S, He Q, Wang W, et al
    The different replication between nonenveloped and quasi-enveloped hepatitis E virus.
    J Med Virol. 2021 Jun 2. doi: 10.1002/jmv.27121.
    PubMed     Abstract available

  117. WANG Y, Li X, Chen Q, Jiao F, et al
    The relationship between liver pathological inflammation degree and pyroptosis in chronic hepatitis B patients.
    J Med Virol. 2021 Jun 1. doi: 10.1002/jmv.27114.
    PubMed     Abstract available

  118. SAJJAD M, Ali S, Baig S, Sharafat S, et al
    HBV S antigen evolution in the backdrop of HDV infection affects epitope processing and presentation.
    J Med Virol. 2021;93:3714-3729.
    PubMed     Abstract available

  119. JACKSON K, Tekoaua R, Li X, Locarnini S, et al
    Real-world application of the Xpert(R) HBV viral load assay on serum and dried blood spots.
    J Med Virol. 2021;93:3707-3713.
    PubMed     Abstract available

    April 2021
  120. XU Z, Lin JZ, Zeng YF, Yang XH, et al
    Changes of cytokine levels and T cell surface molecules in patients with chronic hepatitis B and the association with functional cure.
    J Med Virol. 2021 Apr 29. doi: 10.1002/jmv.27041.
    PubMed     Abstract available

  121. BULFONI M, Pravisani R, Dalla E, Cesselli D, et al
    miRNA expression profiles in liver grafts of HCV and HIV/HCV infected recipients, six months after liver transplantation.
    J Med Virol. 2021 Apr 5. doi: 10.1002/jmv.26999.
    PubMed     Abstract available

    April 2019
  122. EL KASSAS M, Alboraie M, Omar H, El Latif YA, et al
    High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naive and experienced chronic hepatitis C genotype 4: Real world results.
    J Med Virol. 2019 Apr 5. doi: 10.1002/jmv.25478.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge.